• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/10/21 11:14:27 AM ET
    $LH
    Medical Specialities
    Health Care
    Get the next $LH alert in real time by email
    SC 13G/A 1 tv01244-laboratorycorpofamer.htm SCHEDULE 13G/A laboratorycorpofamericaholdings

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 10)*

    Name of issuer:  Laboratory Corp. of America Holdings

    Title of Class of Securities:  Common Stock

    CUSIP Number:  50540R409

    Date of Event Which Requires Filing of this Statement: December 31, 2020

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  50540R409

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    162,958

    7.  SOLE DISPOSITIVE POWER

    9,976,036

    8.  SHARED DISPOSITIVE POWER

    429,566

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    10,405,602

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    10.68%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Laboratory Corp. of America Holdings

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    358 South Main Street
    Burlington, North Carolina 27215

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    50540R409

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

    10,405,602

      (b) Percent of Class:

    10.68%

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  0

    (ii)  shared power to vote or direct to vote:  162,958

    (iii)  sole power to dispose of or to direct the disposition of:  9,976,036

    (iv)  shared power to dispose or to direct the disposition of:  429,566

    Comments:

     

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    Not applicable

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    See Attached Appendix A

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 8, 2021

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

     

     

    Appendix A

    Subsidiary:

    Vanguard Asset Management, Limited

    Vanguard Fiduciary Trust Company

    Vanguard Global Advisors, LLC

    Vanguard Group (Ireland) Limited

    Vanguard Investments Australia Ltd

    Vanguard Investments Canada Inc.

    Vanguard Investments Hong Kong Limited

    Vanguard Investments UK, Limited

    *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G

     

    Get the next $LH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LH

    DatePrice TargetRatingAnalyst
    4/2/2025$276.00Buy
    Redburn Atlantic
    3/4/2025$250.00 → $300.00Neutral → Buy
    Citigroup
    1/7/2025$260.00 → $265.00In-line → Outperform
    Evercore ISI
    12/10/2024$265.00 → $275.00Buy
    Jefferies
    10/30/2024Hold → Buy
    HSBC Securities
    10/1/2024$235.00Neutral
    Piper Sandler
    3/25/2024$250.00Hold → Buy
    Argus
    2/26/2024$260.00Outperform
    Leerink Partners
    More analyst ratings

    $LH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Labcorp Launches Labcorp Whole Health Solutions to Support Holistic Care

      New offering delivers convenient, comprehensive lab testing solutions for functional medicine, integrative medicine and primary care providers BURLINGTON, N.C., June 18, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp Whole Health Solutions to support the growing needs of functional medicine, integrative medicine and primary care providers in delivering holistic care. The solution launches specialized test panels and a tailored test menu of more than 1,000 scientifically backed biomarkers for cardiometabolic health, hormones, micronutrients, longevity and whole body wellness.

      6/18/25 7:00:00 AM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp Expands Oncology Portfolio to Improve Patient Care and Advance Cancer Research

      New test offerings target solid tumors and hematologic malignancies Enhanced biopharma services support accelerated clinical trials and companion diagnostic development BURLINGTON, N.C., May 30, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology portfolio. The additions include new test offerings for solid tumor and hematologic malignancies and enhanced biopharma solutions designed to accelerate clinical trials and companion diagnostic development. "Labcorp is comm

      5/30/25 7:00:00 AM ET
      $LH
      Medical Specialities
      Health Care
    • SOLVD Health Appoints Mike Aicher and Vince Cebula to Board of Directors to Support Next Phase of Growth

      SOLVD Health (SOLVD), a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, has appointed diagnostics pioneer Mike Aicher and strategic advisor Vince Cebula to its Board of Directors. Their combined leadership in molecular diagnostics, healthcare technology, and growth-stage investment will support the company's continued expansion as it scales access to personalized health insights and accelerates development of its precision diagnostics platform. Aicher's expertise in building and scaling diagnostic platforms will be instrumental as SOLVD Health expands its personalized health solutions. He brings more than three decades of executiv

      5/12/25 9:00:00 AM ET
      $LH
      Medical Specialities
      Health Care

    $LH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Redburn Atlantic initiated coverage on Labcorp Holdings Inc. with a new price target

      Redburn Atlantic initiated coverage of Labcorp Holdings Inc. with a rating of Buy and set a new price target of $276.00

      4/2/25 8:50:29 AM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp Holdings Inc. upgraded by Citigroup with a new price target

      Citigroup upgraded Labcorp Holdings Inc. from Neutral to Buy and set a new price target of $300.00 from $250.00 previously

      3/4/25 7:36:42 AM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp Holdings Inc. upgraded by Evercore ISI with a new price target

      Evercore ISI upgraded Labcorp Holdings Inc. from In-line to Outperform and set a new price target of $265.00 from $260.00 previously

      1/7/25 8:12:52 AM ET
      $LH
      Medical Specialities
      Health Care

    $LH
    SEC Filings

    See more
    • SEC Form 144 filed by Labcorp Holdings Inc.

      144 - LABCORP HOLDINGS INC. (0000920148) (Subject)

      6/11/25 4:29:47 PM ET
      $LH
      Medical Specialities
      Health Care
    • SEC Form 144 filed by Labcorp Holdings Inc.

      144 - LABCORP HOLDINGS INC. (0000920148) (Subject)

      6/3/25 11:55:38 AM ET
      $LH
      Medical Specialities
      Health Care
    • SEC Form SD filed by Labcorp Holdings Inc.

      SD - LABCORP HOLDINGS INC. (0000920148) (Filer)

      5/30/25 11:18:20 AM ET
      $LH
      Medical Specialities
      Health Care

    $LH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Anderson Kerrii B sold $130,000 worth of shares (500 units at $260.00), decreasing direct ownership by 4% to 12,666 units (SEC Form 4)

      4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

      6/12/25 10:07:20 AM ET
      $LH
      Medical Specialities
      Health Care
    • EVP, Pres of ED, CMO & CSO Caveney Brian J sold $494,000 worth of shares (2,000 units at $247.00), decreasing direct ownership by 6% to 30,067 units (SEC Form 4)

      4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

      6/5/25 8:19:38 AM ET
      $LH
      Medical Specialities
      Health Care
    • President & CEO Schechter Adam H sold $1,518,497 worth of shares (6,105 units at $248.73), decreasing direct ownership by 6% to 98,962 units (SEC Form 4)

      4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

      5/13/25 10:01:55 AM ET
      $LH
      Medical Specialities
      Health Care

    $LH
    Financials

    Live finance-specific insights

    See more
    • Labcorp Announces 2025 First Quarter Results

      Updates Full-Year Guidance Results from Operations for first quarter 2025 versus first quarter last year:Revenue: $3.35 billion versus $3.18 billionDiluted EPS: $2.52 versus $2.69Adjusted EPS: $3.84 versus $3.68Reaffirmed Revenue and Free Cash Flow guidance, raised midpoint of adjusted EPS:Revenue guidance of 6.7% to 8.0%Adjusted EPS range of $15.70 to $16.40; midpoint raised $0.05Free Cash Flow of $1.10 billion to $1.25 billionProviding broader access to comprehensive testing and laboratory services with several transactions announced/completed year-to-dateIntroduced new tests including Labcorp Plasma Complete, a liquid biopsy test for cancer, and pTau-217/Beta Amyloid 42 Ratio test to aid

      4/29/25 6:50:00 AM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp Declares Quarterly Dividend

      BURLINGTON, N.C., April 10, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on June 11, 2025, to stockholders of record as of the close of business on May 29, 2025. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confid

      4/10/25 6:50:00 AM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp to Announce First Quarter Financial Results on April 29, 2025

      BURLINGTON, N.C., March 31, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2025 before the market opens on Tuesday, April 29, 2025. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Participan

      3/31/25 4:15:00 PM ET
      $LH
      Medical Specialities
      Health Care